Fuente: PubMed "nature biotechnology" J Pharm Pharmacol. 2026 Jun 2;78(6):rgag068. doi: 10.1093/jpp/rgag068.ABSTRACTBACKGROUND: Breast cancer is the most common malignant tumor among women worldwide, and conventional chemotherapy faces major challenges including poor targeting, severe systemic toxicity, and drug resistance.OBJECTIVE: This review analyzes the application of nano-drug delivery systems (NDDS) in improving breast cancer chemotherapy, with a particular focus on recent advances in nanocarrier-based targeting strategies.METHODS: This review systematically outlines the current epidemiology and clinical treatment landscape of breast cancer, and provides a detailed analysis of various drug delivery systems (e.g., liposomes, polymeric micelles, inorganic nanoparticles) and their targeting mechanisms, including passive, active, and physicochemical-responsive targeting.RESULTS: NDDS enhance tumor-selective uptake and therapeutic efficacy while reducing side effects, especially active-targeting systems modified with small-molecule ligands such as biotin. Furthermore, NDDS can circumvent multidrug resistance by inhibiting efflux pumps and modulating the tumor microenvironment.CONCLUSION: Nano-drug delivery systems represent a promising disease-modifying approach for precise breast cancer treatment, though challenges remain in clinical translation, which may be overcome through interdisciplinary collaboration and systematic optimization.PMID:42323898 | DOI:10.1093/jpp/rgag068